^
Association details:
| Biomarker: | CHD1 deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide capsule) (Androgen receptor inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Circulting Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer
Published date:
03/26/2021
Excerpt:
Men who had progression-free survival of ≤3 months despite enzalutamide/abiraterone treatment were more likely to have baseline CTC genomic loss of CHD1, PTEN, PHLPP1, and ZFHX3 and gains of BRCA2, KDM5D, MYCN, and SPARC.
DOI:
10.1158/1541-7786.MCR-20-0975
Trial ID:
